Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 351125 in active rheumatoid arthritis
NL-OMON24887Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in rheumatoid arthritis (RA) comparing SCH 351125 with Placebo (2 arms). Primary endpoints: Effect on mononuclear cell migration into synovial tissue and Safety and tolerability. Started Mar 2004; status: active, not recruiting.
02
Drugs
ancriviroc besylate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON24887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24887.